EHA 2024 – Umberto Vitolo

Umberto Vitolo discusses emerging T-cell–engaging agents for B-cell lymphomas and their potential impact. He highlights the effectiveness of bispecific antibody therapy in later-line follicular lymphoma and shares insights from the EPCORE NHL-1 study, highlighting key safety and tolerability precautions for patients receiving the bispecific antibody epcoritamab.

Here is the full EHA 2024 report.